Hartl L; Haslinger K; Angerer M; Semmler G; Schneeweiss-Gleixner M; Jachs M; Simbrunner B; Bauer DJM; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Lampichler K; Halilbasic E; Stättermayer AF; Ba-Ssalamah A; Mandorfer M; Scheiner B; Reiberger T; Trauner M, 2022. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.  Hepatology.

Semmler G; Lindorfer A; Schaefer B; Bartl S; Hametner-Schreil S; Gensluckner S; Balcar L; Pomej K; Lampichler K; Trauner M; Aigner E; Datz C; Zoller H; Hofer H; Schoefl R; Mandorfer M; Reiberger T; Scheiner B, 2022. Outcome of Budd-Chiari Syndrome (BCS) patients treated with direct oral anticoagulants (DOACs) - an Austrian multicenter study.  Clin Gastroenterol Hepatol.

Wöran K; Semmler G; Jachs M; Simbrunner B; Bauer DJM; Binter T; Pomej K; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Lampichler K; Pinter M; Trauner M; Mandorfer M; Stift J; Reiberger T; Scheiner B, 2022. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension.  Clin Gastroenterol Hepatol 20(2):e251-e266

Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M, 2022. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.  Clin Gastroenterol Hepatol 20(6):1362-1373.e6

Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M, 2022. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.  J Hepatol 76(2):353-363

Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T, 2022. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.  Dig Liver Dis 54(4):500-508

Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M, 2022. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.  J Hepatol 76(4):812-821

Burghart L; Halilbasic E; Schwabl P; Simbrunner B; Stättermayer AF; Petrenko O; Scheiner B; Bauer D; Pinter M; Boztug K; Mandorfer M; Trauner M; Reiberger T, 2022. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.  J Gastroenterol 57(2):99-110

Scheiner B; Pinter M, 2022. Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?"  J Hepatol 76(4):988-989

Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M, 2022. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.  Thromb Haemost 122(3):353-362

Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Stättermayer AF; Semmler G; Pinter M; Ay C; Quehenberger P; Trauner M; Reiberger T; Lisman T; Mandorfer M, 2022. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.  J Hepatol 76(5):1090-1099

D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Gaillard VE; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Personeni N; Pressiani T; Sharma R; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ, 2022. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.  Hepatology.

Scheiner B; Pinter M, 2022. Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".  J Hepatol.

Hartl L; Haslinger K; Angerer M; Jachs M; Simbrunner B; Bauer DJM; Semmler G; Scheiner B; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Trauner M; Mandorfer M; Reiberger T, 2022. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients.  Liver Int.

Jachs M; Scheiner B; Pinter M, 2022. Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.  J Hepatol.

Himmelsbach V; Pinter M; Scheiner B; Venerito M; Sinner F; Zimpel C; Marquardt JU; Trojan J; Waidmann O; Finkelmeier F, 2022. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.  Cancers (Basel) 14.

Bucsics T; Lampichler K; Vierziger C; Schoder M; Wolf F; Bauer D; Simbrunner B; Hartl L; Jachs M; Scheiner B; Trauner M; Gruenberger T; Karnel F; Mandorfer M; Reiberger T, 2022. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.  Dig Dis Sci.

de Castro T; Jochheim LS; Bathon M; Welland S; Scheiner B; Shmanko K; Roessler D; Khaled NB; Jeschke M; Ludwig JM; Marquardt JU; Weinmann A; Pinter M; Lange CM; Vogel A; Saborowski A, 2022. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.  Ther Adv Med Oncol 14:17588359221080298

Scheiner B; Pinter M, 2022. Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".  J Hepatol 76(5):1233-1234

Pinter M; Scheiner B; Peck-Radosavljevic M, 2021. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.  Gut 70(1):204-214

Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T, 2021. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.  Dig Liver Dis 53(3):345-352

Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T, 2021. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.  J Hepatol 74(4):819-828

Eder M; Omic H; Gorges J; Badt F; Kikic Z; Saemann MD; Tong A; Bauer D; Semmler G; Reiberger T; Lagler H; Scheiner B, 2021. Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease.  PLoS One 16(4):e0249785

Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T, 2021. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.  Gut 70(9):1758-1767

Paternostro R; Bardach C; Hofer BS; Scheiner B; Schwabl P; Asenbaum U; Ba-Ssalamah A; Scharitzer M; Bucscis T; Simbrunner B; Bauer D; Trauner M; Mandorfer M; Reiberger T; Lampichler K, 2021. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension.  Liver Int 41(4):799-809

Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M, 2021. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.  Nature 592(7854):450-456

Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M, 2021. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.  United European Gastroenterol J 9(2):209-219

Semmler G; Binter T; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Gavasso S; Chromy D; Bauer DJM; Simbrunner B; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Steindl-Munda P; Schöfl R; Russo FP; Simioni P; Trauner M; Ferenci P; Reiberger T; Mandorfer M, 2021. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.  Hepatology 73(4):1275-1289

Semmler G; Binter T; Kozbial K; Schwabl P; Chromy D; Bauer D; Simbrunner B; Müllner-Bucsics T; Scheiner B; Stättermayer A; Pinter M; Steindl-Munda P; Trauner M; Ferenci P; Reiberger T; Mandorfer M, 2021. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR.  J Pers Med 11.

Pomej K; Balcar L; Scheiner B; Semmler G; Meischl T; Mandorfer M; Reiberger T; Müller C; Trauner M; Pinter M, 2021. Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.  J Hepatocell Carcinoma 8:1485-1493

Hartl L; Jachs M; Desbalmes C; Schaufler D; Simbrunner B; Paternostro R; Schwabl P; Bauer DJM; Semmler G; Scheiner B; Bucsics T; Eigenbauer E; Marculescu R; Szekeres T; Peck-Radosavljevic M; Kastl S; Trauner M; Mandorfer M; Reiberger T, 2021. The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes.  Hepatol Int 15(5):1160-1173

Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J, 2021. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.  Am J Gastroenterol 116(4):723-732

Balcar L; Semmler G; Pomej K; Simbrunner B; Bauer D; Hartl L; Jachs M; Paternostro R; Bucsics T; Pinter M; Trauner M; Mandorfer M; Reiberger T; Scheiner B, 2021. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.  United European Gastroenterol J 9(4):427-437

Semmler G; Pomej K; Bauer DJM; Balcar L; Simbrunner B; Binter T; Hartl L; Becker J; Pinter M; Quehenberger P; Trauner M; Mandorfer M; Lisman T; Reiberger T; Scheiner B, 2021. Safety of direct oral anticoagulants in patients with advanced liver disease.  Liver Int 41(9):2159-2170

Hartl L; Semmler G; Hofer BS; Schirwani N; Jachs M; Simbrunner B; Bauer DJM; Binter T; Pomej K; Pinter M; Trauner M; Mandorfer M; Reiberger T; Scheiner B, 2021. COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality.  Hepatol Commun 5(10):1660-1675

Finkelmeier F; Scheiner B; Leyh C; Best J; Fründt TW; Czauderna C; Beutel A; Bettinger D; Weiß J; Meischl T; Kütting F; Waldschmidt DT; Radu P; Schultheiß M; Peiffer KH; Ettrich TJ; Weinmann A; Wege H; Venerito M; Dufour JF; Lange CM; Pinter M; Waidmann O, 2021. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.  Liver Cancer 10(4):360-369

Muhammed A; Fulgenzi CAM; Dharmapuri S; Pinter M; Balcar L; Scheiner B; Marron TU; Jun T; Saeed A; Hildebrand H; Muzaffar M; Navaid M; Naqash AR; Gampa A; Ozbek U; Lin JY; Perone Y; Vincenzi B; Silletta M; Pillai A; Wang Y; Khan U; Huang YH; Bettinger D; Abugabal YI; Kaseb A; Pressiani T; Personeni N; Rimassa L; Nishida N; Di Tommaso L; Kudo M; Vogel A; Mauri FA; Cortellini A; Sharma R; D'Alessio A; Ang C; Pinato DJ, 2021. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.  Cancers (Basel) 14.

Pomej K; Scheiner B; Hartl L; Balcar L; Meischl T; Mandorfer M; Reiberger T; Müller C; Trauner M; Pinter M, 2021. COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital.  PLoS One 16(8):e0256544

Hartl L; Jachs M; Simbrunner B; Bauer DJM; Semmler G; Gompelmann D; Szekeres T; Quehenberger P; Trauner M; Mandorfer M; Scheiner B; Reiberger T, 2021. Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19.  J Pers Med 11.

Scheiner B; Pinter M, 2020. Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma".  Liver Cancer 9(1):107

Unger LW; Forstner B; Muckenhuber M; Scheuba K; Eigenbauer E; Scheiner B; Pfisterer N; Paternostro R; Trauner M; Mandorfer M; Reiberger T, 2020. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.  Dig Dis Sci 65(9):2712-2718

Scheiner B; Northup PG; Gruber AB; Semmler G; Leitner G; Quehenberger P; Thaler J; Ay C; Trauner M; Reiberger T; Lisman T; Mandorfer M, 2020. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.  Liver Int 40(6):1415-1426

Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M, 2020. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.  Liver Int 40(2):393-404

Simbrunner B; Beer A; Wöran K; Schmitz F; Primas C; Wewalka M; Pinter M; Dolak W; Scheiner B; Puespoek A; Trauner M; Oberhuber G; Mandorfer M; Reiberger T, 2020. Portal hypertensive gastropathy is associated with iron deficiency anemia.  Wien Klin Wochenschr 132(1-2):1-11

Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M, 2020. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.  United European Gastroenterol J 8(3):321-331

Schwarzer R; Reiberger T; Mandorfer M; Kivaranovic D; Hametner S; Hametner S; Paternostro R; Scheiner B; Schneeweiss-Friedl J; Trauner M; Schoefl R; Maieron A, 2020. The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.  J Gastroenterol 55(5):533-542

Scheiner B; Kirstein MM; Pinter M, 2020. Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?"  Liver Cancer 9(1):110-111

Scheiner B; Semmler G; Maurer F; Schwabl P; Bucsics TA; Paternostro R; Bauer D; Simbrunner B; Trauner M; Mandorfer M; Reiberger T, 2020. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.  Liver Int 40(1):194-204

Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T, 2020. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.  Liver Int 40(7):1713-1724

Kirstein MM; Scheiner B; Marwede T; Wolf C; Voigtländer T; Semmler G; Wacker F; Manns MP; Hinrichs JB; Pinter M; Vogel A, 2020. Sequential systemic treatment in patients with hepatocellular carcinoma.  Aliment Pharmacol Ther 52(1):205-212

Kirstein MM; Scheiner B; Pinter M; Vogel A, 2020. Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma-authors' reply.  Aliment Pharmacol Ther 52(5):917-918

Stift J; Semmler G; Wöran K; Simbrunner B; Scheiner B; Schwabl P; Paternostro R; Pinter M; Stättermayer AF; Meischl T; Beer A; Trauner M; Mandorfer M; Reiberger T, 2020. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy.  Dig Liver Dis 52(12):1473-1479

Raeven P; Baron-Stefaniak J; Simbrunner B; Stadlmann A; Schwabl P; Scheiner B; Schaden E; Eigenbauer E; Quehenberger P; Mandorfer M; Baron DM; Reiberger T, 2020. Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension.  Hepatol Int 14(6):1083-1092

Pomej K; Scheiner B; Park D; Bauer D; Balcar L; Meischl T; Mandorfer M; Reiberger T; Müller C; Trauner M; Pinter M, 2020. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib.  Cancers (Basel) 12.

Simbrunner B; Semmler G; Stadlmann A; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Bauer D; Eigenbauer E; Pinter M; Stättermayer AF; Quehenberger P; Marculescu R; Trauner M; Mandorfer M; Reiberger T, 2020. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.  Hepatol Int 14(6):1093-1103

Spahn S; Roessler D; Pompilia R; Gabernet G; Gladstone BP; Horger M; Biskup S; Feldhahn M; Nahnsen S; Hilke FJ; Scheiner B; Dufour JF; De Toni EN; Pinter M; Malek NP; Bitzer M, 2020. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.  Cancers (Basel) 12.

Scheiner B; Northup PG; Lisman T; Mandorfer M, 2020. Author response to Letter to the Editor: 'AB0, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?'  Liver Int 40(7):1790-1791

Scheiner B; Kirstein M; Popp S; Hucke F; Bota S; Rohr-Udilova N; Reiberger T; Müller C; Trauner M; Peck-Radosavljevic M; Vogel A; Sieghart W; Pinter M, 2019. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.  Liver Cancer 8(3):203-217

Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M, 2019. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.  Liver Int 39(1):127-135

Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM, 2019. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.  Liver Int 39(4):714-726

Stift J; Semmler G; Walzel C; Mandorfer M; Schwarzer R; Schwabl P; Paternostro R; Scheiner B; Wöran K; Pinter M; Stättermayer AF; Trauner M; Peck-Radosavljevic M; Ferlitsch A; Reiberger T, 2019. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.  Dig Liver Dis 51(8):1144-1151

Chromy D; Mandorfer M; Bucsics T; Schwabl P; Scheiner B; Schmidbauer C; Aichelburg MC; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T, 2019. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.  United European Gastroenterol J 7(4):507-516

Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T, 2019. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.  AIDS Patient Care STDS 33(5):197-206

Semmler G; Simbrunner B; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Bauer D; Pinter M; Ferenci P; Trauner M; Mandorfer M; Reiberger T, 2019. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.  J Gastroenterol Hepatol 34(12):2164-2172

Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M, 2019. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.  Dig Dis Sci 64(12):3642-3651

Simbrunner B; Röthenbacher A; Haslacher H; Bauer D; Chromy D; Bucsics T; Schwabl P; Paternostro R; Scheiner B; Trauner M; Mandorfer M; Schwarzinger I; Reiberger T, 2019. Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.  United European Gastroenterol J 7(5):651-661

Scheiner B; Pinter M, 2019. Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers. Authors' reply.  Aliment Pharmacol Ther 50(2):231-232

Scheiner B; Pinter M, 2019. Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma-authors' reply.  Aliment Pharmacol Ther 50(3):341-342

Scheiner B; Ulbrich G; Mandorfer M; Reiberger T; Müller C; Waneck F; Trauner M; Kölblinger C; Ferlitsch A; Sieghart W; Peck-Radosavljevic M; Pinter M, 2019. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.  United European Gastroenterol J 7(6):850-858

Unger LW; Forstner B; Schneglberger S; Muckenhuber M; Eigenbauer E; Bauer D; Scheiner B; Mandorfer M; Trauner M; Reiberger T, 2019. Guideline-conform statin use reduces overall mortality in patients with compensated liver disease.  Sci Rep 9(1):11674

Unger LW; Forstner B; Schneglberger S; Muckenhuber M; Eigenbauer E; Scheiner B; Mandorfer M; Trauner M; Reiberger T, 2019. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease.  Wien Klin Wochenschr 131(17-18):395-403

Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T, 2019. The impact of hepatic steatosis on portal hypertension.  PLoS One 14(11):e0224506

Chromy D; Schwabl P; Bucsics T; Scheiner B; Strassl R; Mayer F; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T; Mandorfer M, 2018. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.  Wien Klin Wochenschr 130(3-4):105-114

Scheiner B; Funk GC, 2018. Reply to: "Acid-base disorders in liver disease".  J Hepatol 68(3):618-619

Viveiros A; Finkenstedt A; Schaefer B; Mandorfer M; Scheiner B; Lehner K; Tobiasch M; Reiberger T; Tilg H; Edlinger M; Zoller H, 2018. Transferrin as a predictor of survival in cirrhosis.  Liver Transpl 24(3):343-351

Pfisterer N; Dexheimer C; Fuchs EM; Bucsics T; Schwabl P; Mandorfer M; Gessl I; Sandrieser L; Baumann L; Riedl F; Scheiner B; Pachofszky T; Dolak W; Schrutka-Kölbl C; Ferlitsch A; Schöniger-Hekele M; Peck-Radosavljevic M; Trauner M; Madl C; Reiberger T, 2018. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.  Aliment Pharmacol Ther 47(7):966-979

Piano S; Schmidt HH; Ariza X; Amoros A; Romano A; Hüsing-Kabar A; Solà E; Gerbes A; Bernardi M; Alessandria C; Scheiner B; Tonon M; Maschmeier M; Solè C; Trebicka J; Gustot T; Nevens F; Arroyo V; Gines P; Angeli P, 2018. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.  Clin Gastroenterol Hepatol 16(11):1792-1800.e3

Scheiner B; Stammet PR; Pokorny S; Bucsics T; Schwabl P; Brichta A; Thaler J; Lampichler K; Ba-Ssalamah A; Ay C; Ferlitsch A; Trauner M; Mandorfer M; Reiberger T, 2018. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.  Wien Klin Wochenschr 130(13-14):446-455

Mandorfer M; Scheiner B; Stättermayer AF; Schwabl P; Paternostro R; Bauer D; Schaefer B; Zoller H; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferenci P; Ferlitsch A, 2018. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.  Aliment Pharmacol Ther 48(4):451-459

Bucsics T; Grasl B; Ferlitsch A; Schwabl P; Mandorfer M; Zinober K; Stern R; Chromy D; Scheiner B; Sieghart W; Peck-Radosavljevic M; Trauner M; Reiberger T, 2018. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.  Ultrasound Med Biol 44(12):2578-2586

Mandorfer M; Scheiner B; Reiberger T; Ferlitsch A, 2018. Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Authors' reply.  Aliment Pharmacol Ther 48(7):775-776

Scheiner B; Lindner G; Reiberger T; Schneeweiss B; Trauner M; Zauner C; Funk GC, 2017. Acid-base disorders in liver disease.  J Hepatol 67(5):1062-1073

Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T, 2017. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.  Scand J Gastroenterol 52(9):1008-1015

Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T, 2017. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.  Wien Klin Wochenschr 129(15-16):517-526

Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T, 2017. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.  Aliment Pharmacol Ther 45(1):139-149

Scheiner B; Schwabl P; Steiner S; Bucsics T; Chromy D; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T; Mandorfer M, 2016. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.  Medicine (Baltimore) 95(27):e4061

Mandorfer M; Schwabl P; Steiner S; Scheiner B; Chromy D; Bucsics T; Stättermayer AF; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M, 2016. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.  AIDS 30(7):1039-47

Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T, 2015. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.  PLoS One 10(11):e0143429

Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T, 2014. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.  Liver Int 34(1):69-77

Publication list retrieved from NCBI using ImpactPubs